Abstract
Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have